Willfact

IQYMUNE

Hemoleven

LFB’s plasma-derived biopharmaceuticals

Clinical trials

What we do

The LFB Group develops, manufactures and markets biomedicinal products for the treatment of serious, and often rare, diseases within its areas of expertise, namely immunology, haemostasis, perinatal & intensive care.

More than two-thirds of LFB’s turnover stems from activities relating to rare diseases, meaning a disease that affects less than 1 in 2,000 people. There are more than 6,000 rare diseases in the world today. More than 60% of LFB’s investments in research and development are focused on finding treatments for people who suffer from rare diseases and more than 60% of the products produced by the LFB Group are indicated for rare diseases.

LFB is one of the few companies in the world to offer a therapeutic solution for coagulation factor I (fibrinogen) and coagulation factor XI deficiencies and von Willebrand Disease.